- |||||||||| STG-001 / Stargazer Pharma, tinlarebant (BPN-14967) / Lin BioSci
Review, Journal: Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development. (Pubmed Central) - Jan 27, 2022
Some antidiabetic drugs and nutraceuticals have been reported to reduce RBP4 expression, but more clinical data is needed to evaluate their therapeutical benefits. As regulating RBP4 levels or its activities would benefit a wide range of patients, further research is highly recommended to develop clinically useful RBP4 antagonists or protein synthesis inhibitors.
- |||||||||| STG-001 / Stargazer Pharma
Trial completion: Study of STG-001 in Subjects With Stargardt Disease (clinicaltrials.gov) - Apr 27, 2021
P2a, N=10, Completed,
As regulating RBP4 levels or its activities would benefit a wide range of patients, further research is highly recommended to develop clinically useful RBP4 antagonists or protein synthesis inhibitors. Recruiting --> Completed
- |||||||||| STG-001 / Stargazer Pharma
Trial primary completion date: Study of STG-001 in Subjects With Stargardt Disease (clinicaltrials.gov) - Mar 16, 2021
P2a, N=12, Recruiting,
Recruiting --> Completed Trial primary completion date: Dec 2020 --> Mar 2021
|
